drugset / Trial / NCT07103655
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
Phase 4
Enrolling by invitation
132 enrolled
Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.
Timeline
- Start
- 2026-03-01
- Primary completion
- 2026-11-01
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mavacamten | Small molecule | — | — |
| Background | Bisoprolol | Other / unclassified | — | — |
| Background | Carvedilol | Other / unclassified | — | — |
| Background | Diltiazem | Small molecule | — | — |
| Background | Metoprolol | Other / unclassified | — | — |